We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00024076
First Posted: January 27, 2003
Last Update Posted: October 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
  Purpose

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.


Condition Intervention Phase
Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma Procedure: radiofrequency ablation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation of Pulmonary Malignancy

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 30
Study Start Date: May 2000
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
  • Determine the efficacy of this treatment, in terms of local control, in these patients.
  • Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of a primary or secondary intrathoracic malignancy

    • Any cell type or origin
    • Involving the intrapulmonary, mediastinal, or pleural/chest wall
    • Inoperable primary or metastatic cancer to the lung
  • Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
  • Single or multiple lesions that are non-contiguous with vital structures or organs such as:
  • Trachea
  • Heart
  • Aorta
  • Great vessels
  • Esophagus
  • Less than 5 cm in largest dimension
  • Accessible via percutaneous transthoracic route
  • Hepatic:

    • Coagulation profile normal
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00024076


Locations
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Robert D. Suh, MD Jonsson Comprehensive Cancer Center
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00024076     History of Changes
Other Study ID Numbers: CDR0000068889
P30CA016042 ( U.S. NIH Grant/Contract )
UCLA-9908024
NCI-G01-2011
First Submitted: September 13, 2001
First Posted: January 27, 2003
Last Update Posted: October 30, 2015
Last Verified: July 2012

Keywords provided by Jonsson Comprehensive Cancer Center:
recurrent non-small cell lung cancer
recurrent small cell lung cancer
recurrent malignant mesothelioma
recurrent thymoma and thymic carcinoma
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
pulmonary carcinoid tumor
lung metastases

Additional relevant MeSH terms:
Lung Neoplasms
Mesothelioma
Neoplasm Metastasis
Thymoma
Thymus Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Neoplastic Processes
Pathologic Processes
Neoplasms, Complex and Mixed
Lymphatic Diseases